| scholarly article | Q13442814 |
| P50 | author | Douglas Kline | Q90879576 |
| Roland Tisch | Q97091835 | ||
| Bo Wang | Q97093714 | ||
| Ramiro Diz | Q114526142 | ||
| P2093 | author name string | Li Li | |
| Zuoan Yi | |||
| Aaron J Martin | |||
| Yves Maurice Morillon | |||
| P2860 | cites work | Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction | Q24650734 |
| Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells | Q27860460 | ||
| Genetics, pathogenesis and clinical interventions in type 1 diabetes | Q28281029 | ||
| The CD4-associated tyrosine kinase p56lck is required for lymphocyte chemoattractant factor-induced T lymphocyte migration | Q28293638 | ||
| Suppression of ongoing T cell-mediated autoimmunity by peptide-MHC class II dimer vaccination | Q33727390 | ||
| Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor–specified peripheral niche constraints | Q34096519 | ||
| Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. | Q53859655 | ||
| Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. | Q53885179 | ||
| Mechanisms in CD4 antibody-mediated transplantation tolerance: kinetics of induction, antigen dependency and role of regulatory T cells. | Q54193778 | ||
| TOLERANCE AND SUPPRESSION IN A PRIMED IMMUNE SYSTEM1 | Q61651701 | ||
| In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis | Q67296143 | ||
| Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas | Q69204552 | ||
| Following a diabetogenic T cell from genesis through pathogenesis | Q70488192 | ||
| Insulin-dependent diabetes mellitus | Q71046915 | ||
| The role of CD8+ T cells in the initiation of insulin-dependent diabetes mellitus | Q71420898 | ||
| Nondepleting anti-CD4 has an immediate action on diabetogenic effector cells, halting their destruction of pancreatic beta cells | Q74108273 | ||
| A key role for TGF-beta signaling to T cells in the long-term acceptance of allografts | Q81039592 | ||
| Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes | Q81690799 | ||
| Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes | Q34428346 | ||
| "Infectious" transplantation tolerance. | Q34726892 | ||
| Reprogramming the immune system: co-receptor blockade as a paradigm for harnessing tolerance mechanisms | Q34793904 | ||
| Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance | Q35237468 | ||
| Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial | Q35321191 | ||
| Spontaneous autoimmune diabetes in monoclonal T cell nonobese diabetic mice | Q36380895 | ||
| CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion | Q36399063 | ||
| Single cell analysis shows decreasing FoxP3 and TGFbeta1 coexpressing CD4+CD25+ regulatory T cells during autoimmune diabetes | Q36403481 | ||
| Ligation of the CD4 receptor induces activation-independent down-regulation of L-selectin | Q36432195 | ||
| Human immunodeficiency virus type 1 gp120 reprogramming of CD4+ T-cell migration provides a mechanism for lymphadenopathy | Q37191908 | ||
| Type 1 diabetes development requires both CD4+ and CD8+ T cells and can be reversed by non-depleting antibodies targeting both T cell populations. | Q37425120 | ||
| Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus | Q40581531 | ||
| Evidence for the role of CD8+ cytotoxic T cells in the destruction of pancreatic beta-cells in nonobese diabetic mice. | Q41487658 | ||
| Emerging roles for the TGFbeta family in pancreatic beta-cell homeostasis | Q42113167 | ||
| The induction of skin graft tolerance in major histocompatibility complex-mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti-CD4 and anti-CD8 antibodies | Q43414853 | ||
| Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T cell clone | Q44534362 | ||
| The use of a non-depleting anti-CD4 monoclonal antibody to re-establish tolerance to beta cells in NOD mice. | Q44587253 | ||
| Dynamic reorganization of chemokine receptors, cholesterol, lipid rafts, and adhesion molecules to sites of CD4 engagement | Q45303209 | ||
| Prevention of early loss of transplanted islets in the liver of mice by adenosine. | Q45936359 | ||
| TGF-beta1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype | Q46431455 | ||
| Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation | Q46881246 | ||
| Induction of foxP3+ regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants | Q47644499 | ||
| TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes | Q47667692 | ||
| Interleukin-4 deficiency does not exacerbate disease in NOD mice | Q47690788 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported | Q19125045 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2871-2880 | |
| P577 | publication date | 2012-06-29 | |
| P1433 | published in | Diabetes | Q895262 |
| P1476 | title | Long-term remission of diabetes in NOD mice is induced by nondepleting anti-CD4 and anti-CD8 antibodies | |
| P478 | volume | 61 |
| Q63246493 | Anti-CD8 monoclonal antibody-mediated depletion alters the phenotype and behavior of surviving CD8+ T cells |
| Q37351576 | Anti-coreceptor therapy drives selective T cell egress by suppressing inflammation-dependent chemotactic cues |
| Q42737518 | Antibody Binding to CD4 Induces Rac GTPase Activation and Alters T Cell Migration |
| Q90324457 | Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes |
| Q38063547 | Emerging immune therapies in type 1 diabetes and pancreatic islet transplantation |
| Q45700874 | Fasting and meal-stimulated residual beta cell function is positively associated with serum concentrations of proinflammatory cytokines and negatively associated with anti-inflammatory and regulatory cytokines in patients with longer term type 1 dia |
| Q37088180 | Pathogenic mechanisms in type 1 diabetes: the islet is both target and driver of disease |
| Q37351448 | Persistent suppression of type 1 diabetes by a multicomponent vaccine containing a cholera toxin B subunit-autoantigen fusion protein and complete Freund's adjuvant |
| Q38384138 | Reestablishing T Cell Tolerance by Antibody-Based Therapy in Type 1 Diabetes |
| Q58711931 | Single-cell transcriptomics reveal that PD-1 mediates immune tolerance by regulating proliferation of regulatory T cells |
| Q37342952 | Targeted suppression of autoreactive CD8(+) T-cell activation using blocking anti-CD8 antibodies. |
| Q34983677 | Testing agents for prevention or reversal of type 1 diabetes in rodents |
| Q35787117 | The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes |
| Q87135143 | The new insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes |
| Q58773667 | Therapies to Suppress β Cell Autoimmunity in Type 1 Diabetes |
| Q37381434 | Thymic development of autoreactive T cells in NOD mice is regulated in an age-dependent manner |
Search more.